Siena, Italy
Siena, Italy

Time filter

Source Type

Patent
Toscana Biomarkers S.r.l. | Date: 2011-02-16

The present invention refers peptides and methods for the identification of diagnostic antibodies in autoimmune diseases such as Systemic Lupus Erythematosus (SLE), and therefore useful tools for diagnosis or therapeutic treatment of SLE.


Patent
Toscana Biomarkers S.r.l. | Date: 2012-01-04

The present invention refers to citrullinated synthetic peptides derived from the histone H4 protein and their use in the diagnosis of autoimmune diseases, particularly Rheumatoid Arthritis (RA).


Patent
Toscana Biomarkers S.r.l. | Date: 2012-11-28

The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (RA).


Patent
Toscana Biomarkers S.R.L. | Date: 2012-05-24

The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (RA).


Patent
Toscana Biomarkers S.R.L. | Date: 2010-07-23

The present invention refers peptides and methods for the identification of diagnostic antibodies in auto-immune diseases such as Systemic Lupus Erythematosus (SLE), and therefore useful tools for diagnosis or therapeutic treatment of SLE.


Patent
Toscana Biomarkers S.r.l. | Date: 2011-05-25

The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence:G P P W W P P I C D P P Q P S K T Q G Q S X_(1) G Q S X_(2) G X_(3) G X_(4) G X_(5) G X_(6) G X_(7) G K G K S X_(8) D K Q X_(9) K P G G P W X_(10) P E P (SEQ ID No. 1), wherein the amino acids X_(1)-X_(10) are selected independently from an arginine residue or a citrulline residue and at least one of X_(1)-X_(10) is a citrulline residue, or a functional fragment thereof and uses thereof.


Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.01M | Year: 2012

Coding of biochemical information is commonly described to be based solely on nucleotides and amino acids, whereas carbohydrates, the most abundant type of molecule in Nature, appear sidelined in this respect. That carbohydrates, as part of cellular glycoconjugates, have exceptional talents for building biochemical signals is an emerging insight, at the heart of the concept of the Sugar Code. Intuitively, emergence of recognition partners for information transfer is expected, and this is the case. Thus, coding of bioinformation in glycans and information transfer via lectins is key to a wealth of medically relevant processes, e.g. infection, immune regulation and malignancy, now awaiting its full exploitation pharmaceutically. To do so, training in this exceptionally interdisciplinary field needs to be provided. With this aim, scientific and country/gender issues are strategically combined in this network. Its composition assures a continuous chain of research expertise, from computational and synthetic chemistry to state of the art biophysical chemistry and structural biology, then to biochemistry, molecular cell biology and pharmaceutical/biomedical sciences, generating innovative clinical approaches. Notably, academia is linked with industry, bringing in the essence of business acumen into the training programme. This activity and the research deliberately planned as interdisciplinary projects ensure an optimal training for young researchers in a dynamically developing area of conspicuous biopharmaceutical potential. Equally important, it lays the foundation to inspire novel strategies for the design of potent and selective inhibitors against lectins and the development of lectins (or suitably engineered variant(s)) as therapeuticals. As a boon for the success of the network, cooperations between several partners have already proven successful, especially increasing the core in Madrid and partners in Dublin, Munich and Prague.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.2.4.5-2 | Award Amount: 7.31M | Year: 2010

The ALLFUN proposal aims at defining the cellular and molecular mechanisms by which ubiquitous airborne or commensal fungi contribute to immune homeostasis and its dysregulation leading to allergy and inflammatory diseases. Breakthroughs in understanding how mucosal homeostasis is established, maintained or disrupted in the presence of fungi should be sources of new therapeutic targets and drugs (i.e. anti-inflammatory, immunomodulatory and anti-infectious molecules). European scientists representing the leading edge of this field are brought together here in a unique synergistic and cross-cutting collaboration that addresses a major medical and economic problem of considerable importance to the health care sector. The study will be centered on yeasts and filamentous fungi known to be associated with a number of inflammatory, autoimmune and allergic diseases. Via a multidisciplinary systems biology study combining fungal genetics, clinical research and animal models in a systems biology approach, integrating traditional wet-lab methods with those of functional genomics, immunomics, allergomics and bioinformatics, the ALLFUN project meets the criteria of the call, the strategic objective of which is to elucidate mechanisms by which infections may lead to aberrant activation of inflammation, the lack of resolution of which is responsible for inflammatory diseases. The anticipated results are highly relevant to society in terms of reducing the burden of mortality and suffering in patients with fungus-related diseases, identifying more accurate biomarkers for immunological disorders, optimizing and possibly reducing the cost of antifungal therapy by association with anti-inflammatory strategies that targets pathogenicity rather than microbial growth, the host-pathogen interface rather than the pathogen. Understanding the spectrum of immunological responses to fungi is perhaps the single most important challenge in the field of medical mycology.


Grant
Agency: Cordis | Branch: FP7 | Program: BSG-SME | Phase: SME-2012-1 | Award Amount: 1.72M | Year: 2012

Rheumatoid arthritis (RA) and sistemic lupus erythematosus (SLE) are two autoimmune diseases that respectively affect an estimated population of 1.537.000 and 1.272.000 of patients in Europe. Such diseases show a long prodrome during which there are no clinical symptoms. In some cases, therapeutic treatments have been developed to improve patients quality of life. Therefore, reliable diagnostic/prognostic tools are necessary not only for an early diagnosis and for monitoring disease activity, but also for setting up personalized therapeutic treatments. The clinical diagnosis of RA and SLE is assisted by the use of in vitro diagnostic tests aimed at the evaluation of the presence/level of few autoantibodies circulating in serum. Yet, this diagnostic approach is unsatisfactory because it can assist the diagnosis only after the first disease onset, it is not useful to evaluate the disease susceptibility for an early prevention, and it does not provide information to follow the disease progression for the set up of personalized therapeutic treatments. To solve these drawbacks, the GAPAID project is aimed at supplying the SME participants of the scientific and technological activities necessary to develop a novel diagnostic / prognostic platform for patients affected by RA and SLE. To this aim the scientific activities will be focused on the discovery of the diagnostic and prognostic value of the genetic and serological profiles associated to RA and SLE. The technological activities will contribute to develop multiplex arrays for the contemporary detection of more analytes and to set up a software for the RA and SLE diagnosis / prognosis by matching the clinical, genetic, and serological data. The exploitation of the scientific and technological results will allow the SME participants to the GAPAID proposal to develop and to further commercialize both for RA and SLE an in vitro diagnostic product composed by a genetic array, a serological array, and a software.


Patent
Toscana Biomarkers S.R.L. | Date: 2011-06-30

The present invention refers to citrullinated synthetic peptides derived from the histone H4 protein and their use in the diagnosis of autoimmune diseases,particularly Rheumatoid Arthritis (RA).

Loading Toscana Biomarkers Srl collaborators
Loading Toscana Biomarkers Srl collaborators